With the rapid development of biotechnology, immunotherapy has become a bright pearl in the field of modern medicine. In this regard, the iHuPBMC-OncVax platform of InnoModels Biotechnology is playing an important role in drug discovery and immunotherapy with its unique advantages.
First, the iHuPBMC-OncVax platform enables comprehensive immune cell reconstitution. Under this platform, researchers can successfully reconstruct human-derived T cells, B cells, NK cells, macrophages and DC cells in mice. This means that the iHuPBMC-OncVax platform can provide a more comprehensive and realistic human immune environment than conventional PBMC immune system humanization models, thus more accurately simulating the human immune response.

Second, the iHuPBMC-OncVax platform surpasses the limitations of conventional PBMC models. Conventional PBMC models often only reconstruct human-derived T cells or NK cells, but lack the reconstruction of human-derived myeloid cells, and therefore cannot perform antigen presentation. However, the iHuPBMC-OncVax platform successfully solves this problem by enabling the reconstitution of human-derived myeloid cells in mice, thus fulfilling the critical need for antigen presentation. This breakthrough makes the platform more practical and more widely applicable in immunotherapy research.
In addition, the iHuPBMC-OncVax platform is particularly suitable for the evaluation of immunotherapies that require antigen presentation, such as tumor vaccines. By simulating real human immune responses, researchers can more accurately assess the effects of tumor vaccines, thus providing more reliable data support for clinical treatment. This advantage makes the iHuPBMC-OncVax platform pivotal in the field of tumor immunotherapy.
In summary, the iHuPBMC-OncVax platform of InnoModels Biotechnology is playing an important role in the field of immunotherapy with its unique advantages of comprehensive immune cell reconstruction, surpassing the limitations of conventional PBMC models, and being suitable for the evaluation of antigen-presenting immunotherapy. It is believed that in the near future, with the continuous improvement of the platform's technology and the expansion of its application areas, it will play an even more important role in the field of drug discovery and immunotherapy, and make a greater contribution to the cause of human health.